Recommendations by the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the treatment of patients with inflammatory bowel disease associated with spondyloarthritis

Orchard, 1998, Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history, Gut, 42, 387, 10.1136/gut.42.3.387

Hedin, 2019, The pathogenesis of extraintestinal manifestations: implications for IBD Research, Diagnosis, and Therapy, J Crohns Colitis, 13, 541, 10.1093/ecco-jcc/jjy191

Sanz Sanz, 2018, Screening of inflammatory bowel disease and spondyloarthritis for referring patients between Rheumatology and Gastroenterology, Gastroenterol Hepatol, 41, 54, 10.1016/j.gastrohep.2017.03.012

Ibn Yacoub, 2012, Relationship between diagnosis delay and disease features in Moroccan patients with ankylosing spondylitis, Rheumatol Int, 32, 357, 10.1007/s00296-010-1635-7

Pariente, 2011, Development of the Crohn's disease digestive damage score, the Lemann score, Inflamm Bowel Dis, 17, 1415, 10.1002/ibd.21506

Olivieri, 2014, Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease, Autoimmun Rev, 13, 822, 10.1016/j.autrev.2014.04.003

Salvarani, 2009, Clinical features and epidemiology of spondyloarthritides associated with inflammatory bowel disease, World J Gastroenterol, 15, 2449, 10.3748/wjg.15.2449

Peluso, 2015, Management of arthropathy in inflammatory bowel diseases, Ther Adv Chronic Dis, 6, 65, 10.1177/2040622314563929

Juanola Roura, 2011, [Consensus Statement of the Spanish Society of Rheumatology on the management of biologic therapies in spondyloarthritis except for psoriatic arthritis], Reumatol Clin, 7, 113, 10.1016/j.reuma.2010.12.002

Rudwaleit, 2011, The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general, Ann Rheum Dis, 70, 25, 10.1136/ard.2010.133645

Rudwaleit, 2009, The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection, Ann Rheum Dis, 68, 777, 10.1136/ard.2009.108233

Salvarani, 2001, Musculoskeletal manifestations in a population-based cohort of inflammatory bowel disease patients, Scand J Gastroenterol, 36, 1307, 10.1080/003655201317097173

Stolwijk, 2015, The epidemiology of extra-articular manifestations in ankylosing spondylitis: a population-based matched cohort study, Ann Rheum Dis, 74, 1373, 10.1136/annrheumdis-2014-205253

Palm, 2002, Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study), J Rheumatol, 29, 511

Harbord, 2016, The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease, J Crohns Colitis, 10, 239, 10.1093/ecco-jcc/jjv213

Amiot, 2019, Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study, Aliment Pharmacol Ther, 50, 40, 10.1111/apt.15294

Meserve, 2019, Retrospective analysis of safety of vedolizumab in patients with inflammatory bowel diseases, Clin Gastroenterol Hepatol, 17, 1533, 10.1016/j.cgh.2018.09.035

Varkas, 2017, An induction or flare of arthritis and/or sacroilitis by vedolizumab in inflammatory bowel disease: a case series, Ann Rheum Dis, 76, 878, 10.1136/annrheumdis-2016-210233

Poddubnyy, 2015, Development of an ASAS-endorsed recommendation for the early referral of patients with a suspicion of axial spondyloarthritis, Ann Rheum Dis, 74, 1483, 10.1136/annrheumdis-2014-207151

Rudwaleit, 2006, Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria, Arthritis Rheum, 54, 569, 10.1002/art.21619

Sieper, 2009, New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS), Ann Rheum Dis, 68, 784, 10.1136/ard.2008.101501

Dougados, 2011, ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis, Ann Rheum Dis, 70, 249, 10.1136/ard.2010.133488

Braun, 2011, 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis, Ann Rheum Dis, 70, 896, 10.1136/ard.2011.151027

Gonzalez-Alvaro, 2015, Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, Rheumatology (Oxford), 54, 1200, 10.1093/rheumatology/keu461

Gomollon, 2017, 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management, J Crohns Colitis, 11, 3, 10.1093/ecco-jcc/jjw168

Harbord, 2017, Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management, J Crohns Colitis, 11, 769, 10.1093/ecco-jcc/jjx009

Coates, 2014, Systematic review of treatments for psoriatic arthritis: 2014 update for the GRAPPA, J Rheumatol, 41, 2273, 10.3899/jrheum.140875

Carmona Ortells, 2010, [Management of spondyloarthritis (ESPOGUIA): methodology and general data from the document], Reumatol Clin, 6, 1, 10.1016/j.reuma.2009.12.008

Lanas, 2014, [Safe prescription recommendations for non steroidal anti-inflammatory drugs: consensus document ellaborated by nominated experts of three scientific associations (SER-SEC-AEG)], Gastroenterol Hepatol, 37, 107, 10.1016/j.gastrohep.2013.11.014

Sostres, 2016, [Appropriate prescription, adherence and safety of non-steroidal anti-inflammatory drugs], Med Clin (Barc), 146, 267, 10.1016/j.medcli.2015.09.022

Kefalakes, 2009, Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality?, Eur J Clin Pharmacol, 65, 963, 10.1007/s00228-009-0719-3

Hensley, 2015, Use of cyclo-oxygenase inhibitors is not associated with clinical relapse in inflammatory bowel disease: a case-control study, Pharmaceuticals (Basel), 8, 512, 10.3390/ph8030512

Sandborn, 2006, Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study, Clin Gastroenterol Hepatol, 4, 203, 10.1016/j.cgh.2005.12.002

El Miedany, 2006, The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases, Am J Gastroenterol, 101, 311, 10.1111/j.1572-0241.2006.00384.x

Ribaldone, 2015, Coxib's safety in patients with inflammatory bowel diseases: a meta-analysis, Pain Physician, 18, 599, 10.36076/ppj.2015/18/599

Miao, 2014, Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease, Cochrane Database Syst Rev, Cd007744

De Vlam, 2000, Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association, J Rheumatol, 27, 2860

Bandinelli, 2016, Occult spondyloarthritis in inflammatory bowel disease, Clin Rheumatol, 35, 281, 10.1007/s10067-015-3074-z

Sandborn, 2001, Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial, Gastroenterology, 121, 1088, 10.1053/gast.2001.28674

Toussirot, 2012, Development of inflammatory bowel disease during anti-TNF-alpha therapy for inflammatory rheumatic disease: a nationwide series, Joint Bone Spine, 79, 457, 10.1016/j.jbspin.2011.10.001

Braun, 2007, Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents, Arthritis Rheum, 57, 639, 10.1002/art.22669

Yamada, 2019, Systematic review with meta-analysis: risk of new onset IBD with the use of anti-interleukin-17 agents, Aliment Pharmacol Ther, 50, 373, 10.1111/apt.15397

Hueber, 2012, Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial, Gut, 61, 1693, 10.1136/gutjnl-2011-301668

Gisbert, 2015, [Vedolizumab in the treatment of Crohn's disease], Gastroenterol Hepatol, 38, 338, 10.1016/j.gastrohep.2014.12.003

Paccou, 2019, Vedolizumab has no efficacy on articular manifestations in patients with spondyloarthritis associated with inflammatory bowel disease, Joint Bone Spine, 10.1016/j.jbspin.2019.01.008

Poddubnyy, 2014, Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS), Ann Rheum Dis, 73, 817, 10.1136/annrheumdis-2013-204248

Deodhar, 2019, Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis, Arthritis Rheumatol, 71, 258, 10.1002/art.40728

Cabriada, 2013, Gastroenterol Hepatol, 36, 127, 10.1016/j.gastrohep.2013.01.002

Gomollon, 2015, Gastroenterol Hepatol, 38, 24, 10.1016/j.gastrohep.2014.10.002

Feagan, 2019, Incidence of arthritis/arthralgia in inflammatory bowel disease with long-term vedolizumab treatment: post hoc analyses of the GEMINI trials, J Crohns Colitis, 13, 50, 10.1093/ecco-jcc/jjy125

Tadbiri, 2018, Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort, Aliment Pharmacol Ther, 47, 485, 10.1111/apt.14419

Colman, 2015, Optimal doses of methotrexate combined with anti-TNF therapy to maintain clinical remission in inflammatory bowel disease, J Crohns Colitis, 9, 312, 10.1093/ecco-jcc/jjv027

Peyrin-Biroulet, 2014, Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial, Gut, 63, 88, 10.1136/gutjnl-2013-304984

Brahmania, 2014, Physician global assessments or blood tests do not predict mucosal healing in ulcerative colitis, Can J Gastroenterol Hepatol, 28, 325, 10.1155/2014/737349

Maaser, 2019, ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: initial diagnosis, monitoring of known IBD, detection of complications, J Crohns Colitis, 13, 144, 10.1093/ecco-jcc/jjy113

Sturm, 2019, ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects, J Crohns Colitis, 13, 273, 10.1093/ecco-jcc/jjy114

Mitrev, 2017, Review article: Consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases, Aliment Pharmacol Ther, 46, 1037, 10.1111/apt.14368